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AbstrAct
Purpose to analyse trends in hip fracture (HF) rates in 
patients with rheumatoid arthritis (ra) over an extended 
time period (17 years).
Methods this observational retrospective survey 
was performed by reviewing data from the national 
Surveillance System for Hospital Data, which includes 
more than 98% of Spanish hospitals. all hospitalisations 
of patients with ra and HF that were reported from 1999 
to 2015 were analysed. codes were selected using the 
ninth international classification of Diseases, clinical 
Modification: icD-9-cM: ra 714.0 to 714.9 and HF 820.0 
to 820.3. the crude and age-adjusted incidence rate of 
HF was calculated by age and sex strata over the last 
17 years. general lineal models were used to analyse 
trends.
Results Between 1999 and 2015, 6656 HFs occurred 
in patients with ra of all ages (84.25% women, mean 
age 77.5 and 15.75% men, mean age 76.37). the age-
adjusted osteoporotic HF rate was 221.85/100 000 
ra persons/ year (women 227.97; men 179.06). the HF 
incidence rate increased yearly by 3.1% (95% ci 2.1 to 
4.0) during the 1999–2015 period (p<0.001) and was 
more pronounced in men (3.5% (95% ci 2.1 to 4.9)) than 
in women (3.1% (95% ci 2.3 to 4.1)). the female to male 
ratio decreased from 1.54 in 1999 to 1.14 in 2015. 
the average length of hospital stays (alHS) decreased 
(p<0.001) from 16.76 days (SD 15.3) in 1999 to 10.78 
days (SD 7.72) in 2015. age at the time of hospitalisation 
increased (p<0.001) from 75.3 years (SD 9.33) in 1999 to 
79.92 years (SD 9.47) in 2015. there was a total of 326 
(4.9%) deaths during admission, 247 (4.4%) in women and 
79 (7.5%) in men (p<0.001).
Conclusion in Spain, despite the advances that have 
taken place in controlling disease activity and in treating 
osteoporosis, the incidence rate of HF increased in both 
male and female patients with ra.
InTRoduCTIon
Rheumatoid arthritis (RA), a systemic auto-
immune disorder that primarily affects the 
synovial tissues, is one of the most debili-
tating types of arthritis and affects approxi-
mately 0.5%–2% of the world′s population.1 
RA is characterised by functional disability, 
joint damage, reduced quality of life and 
premature mortality. The incidence of RA 
Key messages
What is already known about this subject?
 ► Patients with rheumatoid arthritis (ra) are at in-
creased risk of osteoporosis and osteoporotic 
fractures.
 ► ra is a risk factor for bone fracture in both men and 
women, with comparable risks of fractures at the 
vertebrae and hip.
What does this study add?
 ► the trend of hip fractures rate in patients with ra in 
Spain is increasing.
 ► this increase is more pronounced in men than in 
women.
 ► there is a different epidemiological pattern in the 
incidence of hip fractures in patients with ra versus 
the general population: age-adjusted hip fracture 
rates in women versus men are near the unit; hip 
fractures in patients with  ra occur, on average, 6 
years earlier than in the general population.
How might this impact on clinical practice?
 ► Patients with ra are to be monitored more closely to 
control bone loss and prevent fracture.
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is two to three times more common in women than in 
men.2
Patients with RA are at increased risk of osteoporosis 
and osteoporotic HFs.3–6 Clinical studies have shown that 
the incidence of osteoporosis among patients with RA is 
two times higher than those without RA.6 Bone loss in 
RA has been associated with many factors, among which 
these three stand out: chronic inflammation, use of gluco-
corticoids and physical inactivity. The release of proin-
flammatory cytokines such as interleukin 1 (IL-1), IL-6 
and tumour necrosis factor-α may cause the abnormal 
production of osteoclasts, thus disrupting the equilib-
rium between bone resorption and bone formation.5 7 
Secretion of receptor activator of nuclear factor kappa B 
ligand by activated T lymphocytes has also been shown to 
induce the differentiation of synovial macrophages into 
osteoclasts, thereby leading to bone loss.8 9 Oral glucocor-
ticoids, commonly used to suppress RA-induced inflam-
mation, can promote the loss of bone mass by inhibiting 
the differentiation and activity of osteoblasts by blocking 
bone morphogenetic protein 210 or Wnt/beta-catenin 
pathways.11 In addition, immobility resulting from RA-in-
duced inflammation, muscle pain, weakness and swelling 
may increase the risk of falling to a certain extent,12 thus 
raising the rate of bone fractures.
During the past 15 years, treatments for RA have signifi-
cantly progressed due to the fact that they are applied 
much earlier and are more intensive in nature. Advances 
in the understanding of RA pathogenesis have signifi-
cantly evolved during this period and have led the intro-
duction of biological therapies and new strategies in the 
management of RA known as ‘treat to target’ (T2T).13 
The use of osteoporosis treatments in patients with RA 
(especially bisphosphonates) has also become widely 
adopted, as has the development of new molecules (eg, 
teriparatide and denosumab), which have been incorpo-
rated into the therapeutic arsenal for patients with RA.14
For all of these reasons, it seems reasonable to venture 
that this new RA treatment paradigm may positively 
impact the incidence rate of HF in patients with RA. As 
far as we know, there is no study that has assessed the 
trend of HF in patients with RA.
MeTHods
A retrospective study using the national information 
system for hospital data (Minimum Basic Data Set 
(MBDS) or Conjunto Mínimo Básico de Datos (CMBD)) 
from the Ministry of Health was performed. This 
system contains information about the admission date, 
discharge date, age, sex, geographical region, diagnosis, 
clinical procedures and discharge status (eg, in-hospital 
death and recovery) for all hospitalisations in Spain. The 
CMBD uses clinical codes from the Spanish version of the 
Ninth International Classification of Diseases, Clinical 
Modification (ICD-9-CM), and it includes an estimated 
98% of public hospital admissions, covering 99.5% of the 
Spanish population.15 We assumed that the remaining 
population and hospitalisation information not included 
in the study followed the same epidemiological charac-
teristics.
The unit of analysis were all hospital discharges related 
to RA (ICD-9-CM: 714.0 to 714.9). All cases of proximal 
third of femur fractures corresponding to ICD-9 codes 
820.0 to 820.9 were identified yearly over the study period. 
Only osteoporotic fractures were considered. Patholog-
ical fractures (733.1 to 733.19) (metastases, bone meta-
bolic diseases such as Paget′s disease (M89.9), fractures of 
another femur location (ICD-9 821) or acetabular-pelvic 
fractures (ICD-9 808.0 to 808.9) were excluded, as well 
as fractures related to road accidents (V87.9). Readmis-
sions within 30 days after discharge were eliminated, 
assuming that they were due to the same HF. For each 
case, specific data were gathered including demographic 
data (age, sex, place of residence), patient risk factors, 
comorbidities and complications during their hospital 
stay (secondary diagnoses), as well as the key diagnostic 
techniques used and surgical procedures performed.15 
The following patient age groups were established: 20–39 
years old, 40–59 years old, 60–79 years old and older than 
80 years of age.
statistical methods
The annual hospital admission rate (HAR) by sex, age 
group and year for the population at risk (see below) 
was calculated as the number of hospital discharges per 
100 000 inhabitants/year. The numerators were the 
cases registered in the MBDS and the denominators 
were the population at risk (see below). Additionally, the 
age-adjusted incidence rates were estimated with 95% CI 
using the population at 2015 as the reference popula-
tion. The study period covered (1 January 1999 through 
31 December 2015) was divided into four periods: in 
three 4-year periods (the first from 1999 to 2002, the 
second from 2003 to 2006, the third from 2007 to 2010) 
and the fourth the 5-year period from 2011 to 2015). The 
population at risk was estimated based on the national 
census provided by the National Institute of Statistics 
and assumed a prevalence of RA of 0.5% (both sexes); 
specifically, 0.8% in women and 0.2% in men. This prev-
alence of RA is the one estimated in the EPISER study, 
the last national epidemiological study conducted in 
our country.16 The ALHS was the number of hospitali-
sation days averaged across all hospital discharges. The 
in-hospital case-fatality rate (CFR) was calculated as the 
number of deaths during the hospital stay divided by the 
total number of hospital discharges (percentage), and 
95% CIs were calculated. The change in annual rates 
was analysed by generalised linear models (GLM) with 
Poisson distribution or negative binomial distribution, 
in cases of overdispersed data. The models were thus 
used to estimate the age-adjusted incidence rate ratio 
of the variable ‘year’ with 95% CI; the p-value of the 
association was noted as the result of the trend test. An 
interaction effect for age group and year was included to 
analyse differences in trends. The significance level was 
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established at 1% to account for the use of aggregated 
data.
The following data were collected: gender, age, place 
of residence (nursing home or community), type of 
primary fracture (intracapsular or extracapsular), 
time to intervention and hospital length of stay. Addi-
tionally, the following risk factors for HF were identi-
fied using ICD-9-CM codes in any secondary diagnosis 
field: Cardiac Disease: ICD-9-CM:398.91, 404, 402.11, 
402.91, 428–428.9; Dementia: ICD-9-CM: 290–290.9; 
Delirium ICD-9-CM: 298.9, 293.0, 293.9, 293.8; Chronic 
pulmonary disease ICD-9-CM: 490–496, 500–505, 506.4; 
Cancer ICD-9-CM: 140.0–172.9, 174.0–195.8, 200–208.9, 
V10.0–V10.9; Metastasic cancer: ICD-9-CM:196.0–199.99; 
Cerebrovascular disease ICD-9-CM: 430–438; Malnu-
trition: ICD-9-CM: 260–263.9; Diabetes: ICD-9-CM: 
250.00–250.99; Myocardial infarction: ICD-9-CM: 
410–410.9; Chronic renal failure: ICD-9-CM: 585–586.99, 
582.0–582.9, 583.0–583.7, 588.0–588.9 and Anaemia: 
ICD-9-CM: 280.00–285.99. The age-adjusted Charlson 
Comorbidity Index (CCI) was computed for each 
patient. This index reflects the number and importance 
of comorbid diseases, relies on ICD-9-CM categories and 
was used to adequately adjust for severity of illness. Quan-
titative data are described by the mean and SD or median 
and IQR. Categorical data are expressed by counts and 
percentages. Differences by sex were tested with  χ2 test, 
Student’s t-test and Mann-Whitney tests, as appropriate. 
In all tests, the significance level was p<0.05.
Statistical analyses were performed using IBM SPSS 
V.24.0, Epidat V.4.2 and Stata V.14 computer packages.
The present study received a waiver for informed 
consent from the local ethics committee (Comité de Ética 
de Investigación del Hospital U. Fundación Alcorcón). 
Patient information was anonymised and deidentified 
prior to the analysis.
ResulTs
A total of 338 343 hospital admissions were reported for 
patients with RA during the 17-year study period. The 
338 343 admissions corresponded to a total of 176 097 
patients (117 985 women and 58 112 men).
Of the total hospital admissions, 6657 (2%) were due to 
HF. A number of 5609 (82.25%) out of this total occurred 
in women and 1048 (15.75%) in men. The mean patient 
age was 77.54 years (SD 9.6), 77.76 (SD 9.4) in women 
and 76.37 (SD 11.5) in men (p<0.001). The ALHS was 
13.96 (SD 12.8), 13.98 (SD 12.2) in women and 13.82 
(SD 15.8) in men (p=0.716). The mean value of the CCI 
was 1.66 (SD 1.08), 1.59 (SD 0.7) in women and 2.03 
(SD 1.48) in men (p<0.001). A number of 6383 (95.9%) 
patients were admitted from the emergency room. There 
was a total of 326 (4.9%) deaths, 247 (4.4%) in women 
and 79 (7.5%) in men (p<0.001) (table 1).
The HAR was 221.85/100 000 RA patients/year (95% 
CI 216.52 to 227.18) during the study period. Table 2 
shows the HAR for each year (both genders), and table 3 
shows the specific results by sex. As supplementary mate-
rial, the HARs are shown by age-range and sex (online 
supplementary tables 1–3). The HAR increased expo-
nentially with age (online supplementary figure 1). 
The curves were similar by sex. The HAR was higher in 
females, 304.83/100 000 RA patients/year (95% CI 277.81 
to 333.77) versus 268.50/100 000 RA patients/year (95% 
CI 217.73 to 327.54) in males (p<0.001). Using GLM, an 
annual increase of 3.2% (95% CI 2.1 to 4, p<0.001) was 
observed for both sexes. In models stratified by gender, 
this increase was 3.1% (95% CI 2.3 to 4.1, p<0.001) in 
women and 3.5% (95% CI 2.1 to 4.9, p<0.001) in men 
(figure 1). Trends were different by age groups with inter-
action effect statistically significant. HAR increased in 
both men and women older than 80 years with an annual 
increase of 5.4% (95% CI 4 to 6.8, p<0.001), and in 60–80 
years, this increase was 1.1% (95% CI 0.3 to 1.9, p=0.007). 
In 20–40 years and 40–60 years, HARs estimated a 
decrease of 2.7% (95% CI 1.3 to 4.1, p<0.001) and 3% 
(95% CI 2.1 to 3.8, p<0.001), respectively (figure 2). The 
female to male ratio decreased during the study period 
(from 1.54 in 1999 to 1.14 in 2015), reflecting the differ-
ence in the increased rates (table 3).
The ALHS significantly decreased (p<0.001) from 
16.76 days (SD=15.3 days) in 1999 to 10.78 days (SD=7.72 
days) in 2015 (figure 3 and online supplementary 
table 4). Moreover, age increased (p<0.001) from 75.3 
Table 1  Description of the patients with RA who suffered a hip fracture episode in Spain, between 1999 and 2015 and a 
comparison by sex
Total Women Men P value
n (%) 6657 (100) 5609 (84.2) 1048 (15.7) <0.001
Mean age (SD) 77.54 (9.6) 77.76 (9.4) 76.37 (11.5) <0.001
ALHS, days (SD) 13.96 (12.8) 13.98 (12.2) 13.82 (15.8) 0.716
Mean Charlson Comorbidity Index (SD) 1.66 (1.08) 1.59 (0.7) 2.03 (1.48) <0.001
Diabetes mellitus (%) 1006 (15.1) 840 (15) 166 (15.8) 0.481
Dementia (%) 212 (3.2) 185 (3.3) 27 (2.6) 0.25
Dead during admission, n (%) 326 (4.9) 247 (4.4) 79 (7.5) <0.001
ALHS, average length of hospital stay; RA, rheumatoid arthritis.
 o
n
 10 June 2019 by guest. Protected by copyright.
http://rm
dopen.bmj.com/
R
M
D
 O
pen: first published as 10.1136/rm
dopen-2018-000671 on 4 June 2018. Downloaded from
 
4 Mazzucchelli r, et al. RMD Open 2018;4:e000671. doi:10.1136/rmdopen-2018-000671
RMD Open
years (SD=9.33) in 1999 to 79.92 years (SD=9.47) in 
2015 (figure 3 and online supplementary table 4). The 
in-hospital CFR was 4.9% (4.4% in women and 7.5% in 
men, p<0.001). The in-hospital CFR remained stable 
throughout the study period (online supplementary 
table 5 and figure 2).
dIsCussIon
In the present study, an extended period of time (1999–
2015) was analysed. This allowed us to investigate trends 
in osteoporotic HFs in patients with RA throughout 
Spain. The main findings of our study are as follows: 
first, the trend of HF rate in patients with RA in Spain 
is increasing. This increase is more pronounced in men 
than in women; second, a different epidemiological 
pattern is apparent in the incidence of HFs in patients 
with RA versus the general population, which we discuss 
below.
In our study, we found an increased incidence of 
age-adjusted HFs. We estimate an increase of 3.2% 
per year for both sexes, being more significant in men 
(3.5%) than in women (3.1%). As far as we know, this is 
the first study to evaluate the HF rate trend in patients 
with RA. Several studies have observed a reduction in the 
use of healthcare resources in patients with RA during 
different periods of time. This has been found mainly 
in the number of total joint replacement17–22 and in the 
number of hospital admissions,23 24 although the rela-
tionship vis-à-vis the introduction of T2T and biological 
treatments is weak.25 The initial hypothesis of our study 
was to evaluate whether the introduction of new thera-
peutic strategies in the treatment of patients with RA, 
such as the T2T, biological therapies and antiosteopo-
rotic drugs (bisphosphonates, denosumab and teri-
paratide) during the last 20 years has had a favourable 
impact on the HF rate. Based on our analysis, the answer 
is no. The only data we found that might indicate a 
favourable evolution concerns the fact that throughout 
the study period the average age of patients with HFs 
significantly increased from a mean age of 75.3 years in 
the period 1999–2002 up to 79.03 in the period 2010–
2015. On the other hand, our results contrast with those 
of other international26–30 and national studies31 32 that 
examined general populations. In these studies, a down-
ward trend in the incidence of HF   was observed over the 
last decade. In the general Spanish population, the rate 
of age-adjusted HF has slowed in recent years, especially 
in women younger than 75 years.31–33 The most likely 
explanation as to why we have seen an increase in the 
incidence of HF during the study period is the increasing 
life expectancy of ageing patients with RA. In a different 
analysis of the MBDS, based on a total of 345 000 hospital 
admissions and 18 000 deaths in RA, we found that the 
average age of both the patients admitted to the hospital 
and the age at which they died had increased by about 5 
years throughout the study period (data not shown).
Another explanation, closely related to the previous 
one, is the ageing of the Spanish population. During 
Table 2  Crude and age-adjusted HARs of hip fractures per 100 000 RA patients (of both sexes) by year
Year RA population No of HA Crude HAR
Age-adjusted 
HAR 95% CI
1999 154 688 195 126.06 150.11 129.24 173.64
2000 156 458 256 163.62 195.87 172.09 222.26
2001 158 163 245 154.90 185.38 162.42 210.85
2002 164 981 315 190.93 228.49 203.52 255.84
2003 168 509 324 192.27 232.22 207.30 259.46
2004 171 559 289 168.45 201.25 178.47 226.28
2005 175 149 378 215.82 260.36 234.49 288.41
2006 178 059 372 208.92 249.56 224.63 276.57
2007 181 634 411 226.28 267.17 241.83 294.54
2008 184 555 405 219.45 256.90 232.36 283.36
2009 185 995 431 231.73 266.15 241.52 292.65
2010 186 762 440 235.59 265.35 241.07 291.44
2011 187 416 454 242.24 266.62 242.61 292.39
2012 187 508 474 252.79 272.23 248.28 297.93
2013 186 853 531 284.18 297.53 272.74 323.99
2014 186 298 573 307.57 313.51 288.36 340.27
2015 186 069 564 303.11 303.12 278.61 329.18
1999–2015 3 000 654 6.657 221.85
HA, hospital admission; HAR, hospital admission rate; RA, rheumatoid arthritis.
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the study period, the absolute number of people over 85 
years of age doubled: in 1999, there were 652 680 people 
over the age of 85 and in 2015, there were 1327 014.
In other studies, done in our country, such as the 
national subanalysis of the COMORA study34 35 and the 
EMAR study,36 we know that the management of oste-
oporosis seems to have improved over the years, but it 
remains suboptimal. While in 2002, screening for oste-
oporosis was infrequent in patients with RA and bone 
mineral density measurement was performed only in 
10.8%36; 12 years later in the COMORA study, bone 
density was performed in 36.6% of patients younger than 
50 years and in 58.6% of those aged 50 years and older.35 
On the other hand, we know that in 2002 antiresorptive 
drugs were infrequently prescribed, and 9.4% of patients 
in the EMAR study received treatment with bisphospho-
nates.36 Ten years later, in another study with the same 
design, EMAR2 study,37 36.2% of patients received treat-
ment with bisphosphonates. In the COMORA study, the 
prescription of antiresorptive drugs was not analysed, but 
vitamin D supplementation, however, was more frequent 
in patients younger than 50 years (93.3%) than in those 
aged 50 years and above (75%). And only over half of 
patients (55.2%) were supplemented with vitamin D 
during prednisone treatment, even in patients at high 
risk for osteoporosis.35
Another finding of our study is a different epidemi-
ological pattern of HF from that usually found in the 
general population. First, the age-adjusted HF rates in 
women are only slightly higher versus those of men. In 
our study, 85% of HFs were in women versus 15% in 
men. If we only take into account the absolute number, 
it might seem that the female to male rate is even greater 
than in the general population. However, if we take 
into account the prevalence of RA in Spain,16 which has 
been estimated at 0.5% and with a female to male ratio 
of 4:1, we observe that the age-adjusted HF rates are 
only slightly higher in women versus men, with a 1.23:1 
female to male ratio. In Spain, in the general population 
with HF, the female to male ratio is 3.6:1.31 38 In addition, 
as the increased incidence of HF was greater in men than 
in women, the female to male ratio approaches unity, 
measuring 1.14:1 in 2015. On the other hand, these 
results suggest that the estimate in the EPISER study16 of a 
prevalence of RA in men of 0.2% in our country is under-
estimated. Second, in our study, the incidence of HF rises 
exponentially in men with ageing, as it does in women, 
and at the same age as in women (online supplementary 
figure 1). While in the general population in Spain, the 
age at which the increase begins is slightly older (∼5–10 
years) in men.31 Third and last, in our study we observed 
that the average age at which the HF occurs is 77.5 years, 
while in studies conducted in the general population in 
our country the average is 83.8 years.31 38 Therefore, HFs 
in patients with RA occur, on average, 6 years earlier than 
in the general population. It is also important to note 
that while in the general population the average age at 
which the HF occurs has remained stable at 83 years, 
and in patients with RA the average of age has increased 
from 75.38 years in 1999 to 79.92 years in 2015. This has 
led to a narrowing of the gap between the general popu-
lation and patients with RA from 8.2 years in 1999 to only 
3.81 years in 2015.
As in studies conducted with the general population, 
our study shows that men present a higher mortality 
(7.5% vs 4.4%) and a higher CCI (2.03 vs 1.59) than 
women.
Figure 1  Age-adjusted hospital admission rate (HAR) (per 100 000 RA patients/year) during 1999–2015. RA, rheumatoid 
arthritis.
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Figure 2  Hospital admission rate (HAR) of hip fractures (per 100 000 RA patients/year) by age range and sex. RA, rheumatoid 
arthritis.
Figure 3  Trend of age and average length of hospital stay (ALHS) during 1999–2015.
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Our study has both strengths and limitations. The main 
strength lies in the large sample size over an extended 
period of time and standardised methodology, which 
was maintained throughout the study period and that 
was previously used to investigate HF hospital admissions 
in Spain.31 32 38 39 We believe that the length of the study 
period and the exhaustive data provided by the CMBD 
provide sufficient internal validity, which, in quantita-
tive terms, is seen in the constant frequency of episodes 
detected every year and, in qualitative terms, in the iden-
tification of the age groups at the greatest risk.
We should underscore the limitations of our work. It 
is an observational study, of retrospective nature, and we 
cannot therefore establish a causal relationship with the 
results found. Even if the CMBD provides information 
from a network of hospitals that covers more than 99% of 
the population living in Spain,40 some fractures may have 
escaped the capture area provided by the public hospital 
discharge registry and there may be coding problems. It 
is also possible that there are cases of HF in patients with 
RA in whom RA has not been coded, which would imply 
an underestimation of our results. Another important 
limitation is that the Spanish National Hospital Discharge 
Database (CMBD) does not include any data regarding 
patient treatments or drug consumption. Another rele-
vant constraint on this paper is the lack of similar studies 
to analyse trends on the incidence of HF in patients with 
RA. There are no studies that thereby allow us to compare 
and discuss our results.
In summary, in Spanish patients with RA we observed 
an upward trend in the incidence of HF, both in men and 
in women. We also observed different epidemiological 
patterns than in the general population: a male to female 
ratio near unit, an exponential increase with age in 
both men and women with no age delay in men and an 
age-at-occurrence that was, on average, 6 years earlier 
than in the general population. A delay in the age of the 
fracture and a decrease in the hospital stay were observed. 
Mortality during admission was stable (about 5%) during 
the study period.
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